DrugDashboards

Penicillamine

Penicillamine · PENICILLAMINE 250 mg/1 · Capsule · Oral · Actavis Pharma, Inc.

NDC 00591-4171-01 · 100 CAPSULE in 1 BOTTLE · ANDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$9.29per EAinvoice-surveyed acquisition cost · May 22, 2024
  • Part D plans paid (avg)$56.31per dosage unitgross, before rebates — matched by drug name · 2024
  • Medicaid generic ceiling (FUL)$81.47per CAPweighted avg manufacturer price $46.5549 · Apr 1, 2025877% of what pharmacies pay — higher than 95% of drugs with this benchmark

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 51991-0974-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$17.05per unit
middle half $15.81$28.67 · 483 plans · Apr 1, 2026
Est. net of rebates
≈ $17.05
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
9%of plans cover it
tier 5 · prior auth 6% · step therapy 4% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 6 quarters since 2024.

NADAC price per unit

$0$100.00$200.00May 2024May 2024$9.29
2 price points · per EA · last surveyed Invalid Date · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Estimated fill cost

#30 count
$278.74
#90 count
$836.22

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2024)

$21,335
22 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $6,289.43 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA210976
TE code
AB
Approval date
Jun 24, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Penicillamine (Capsule)

LabelerStrengthFirst seenLast seen
Bausch Health US, LLCPENICILLAMINE 250 mg/1Jul 15, 2026Sep 2, 2026
Breckenridge Pharmaceutical, Inc.PENICILLAMINE 250 mg/1Jul 15, 2026Sep 2, 2026
Cycle Pharmaceuticals Ltd.PENICILLAMINE 250 mg/1Jul 15, 2026Sep 2, 2026
Granules Pharmaceuticals Inc.PENICILLAMINE 250 mg/1Jul 15, 2026Sep 2, 2026
Navinta LLCPENICILLAMINE 250 mg/1Jul 15, 2026Sep 2, 2026
Proficient Rx LPPENICILLAMINE 250 mg/1Jul 15, 2026Sep 2, 2026
Actavis Pharma, Inc.PENICILLAMINE 250 mg/1Jul 15, 2026Aug 28, 2026
Par Health USA, LLCPENICILLAMINE 250 mg/1Aug 7, 2026Aug 28, 2026
Endo USA, Inc.PENICILLAMINE 250 mg/1Jul 15, 2026Aug 5, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Penicillamine — NDC 00591-4171-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00591417101.

Free to cite with attribution — see how the data is put together.